Successful determination of imatinib re-administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction.

Ryosuke Nakahara Takahiro Sumimoto Ryota Tanaka Masao Ogata Hiroki Itoh

Clin Case Rep

Department of Clinical Pharmacy Oita University Hospital Oita Japan.

Published: August 2021

Fixed dose regimens are the usual way of administering tyrosine kinase inhibitors (TKIs).
A recent case report suggests that therapeutic drug monitoring (TDM) could improve individualized dosing of TKIs.
This individualized approach may be especially beneficial for treating chronic myeloid leukemia (CML) patients who are starting dialysis.

Fixed dose regimen is currently the standard administration method for TKI. However, this case report indicated that TDM may by a useful approach to individualized dosing of TKI for the treatment of CML when initiating dialysis.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365396	PMC
http://dx.doi.org/10.1002/ccr3.4357	DOI Listing

Publication Analysis

Top Keywords

initiating dialysis

successful determination

determination imatinib

imatinib re-administration

re-administration dosage

dosage therapeutic

therapeutic drug

drug monitoring

monitoring case

case chronic

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!